Blood Pressure

The combination treatment of two or more antihypertensive therapies in patients being treated with ibrutinib can significantly reduce blood pressure, data published in Blood Advances showed.

The dual incretin agonist tirzepatide reduced 24-hour ambulatory BP for adults with obesity-related hypertension, with the effects potentially independent of weight loss, according to data from a planned substudy of the SURMOUNT-1 trial.

WAILEA, Hawaii — Addressing blood pressure and other underlying health concerns is critical to get the best outcomes in diabetic tractional retinal detachment surgery, according to a speaker at Retina 2024.

Reduced blood lead in American Indians, a population that experienced increased chronic exposure, was associated with reductions in systolic BP and reduced interventricular septum thickness, researchers reported.

Consuming nitrate-rich beetroot juice daily for 12 weeks resulted in decreased blood pressure and better 6-minute walk distance in patients with COPD compared with placebo, according to data published in European Respiratory Journal.

Researchers reported that exposure to elevated LDL and elevated systolic BP before age 55 years is associated with increased coronary heart disease risk independent of later-life BP and cholesterol levels.

One spouse in a heterosexual marriage having hypertension was associated with increased likelihood for the other spouse to have it as well, especially in India and China, but odds were also elevated among couples in the U.S. and England.

Adults who eat more foods associated with a Mediterranean diet have lower blood pressure, BMI and reduced cardiovascular risk, according to study findings published in Nutrition, Metabolism & Cardiovascular Diseases.

PHILADELPHIA — Pegloticase and methotrexate can be used to reduce blood pressure in patients with gout, hinting at a link between serum uric acid level and hypertension, according to data presented at the ASN Kidney Week conference.

PHILADELPHIA — Zilebesiran, an investigational subcutaneous RNA interference therapeutic, lowered systolic blood pressure at 3 months and sustained the reduction to 6 months, according to results of the phase 2 KARDIA-1 trial.